Recent studies have described that pirfenidone, a drug approved for IPF treatment reduces mRNA expression of mmp3 in a profibrotic model of human lung fibroblasts stimulated by TGF-β1 [100]. Here, MMP3 is linked to idiopathic pulmonary fibrosis.